265 Watline Avenue
Mississauga, ON L4Z 1P3
Canada
905 361 8910
https://www.microbix.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter:
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Cameron L. Groome | President, CEO & Director | 416,65k | N/A | N/A |
Mr. James S. Currie | Chief Financial Officer | 266,51k | N/A | N/A |
Dr. Kenneth Hughes Ph.D. | Chief Operating Officer | 266,57k | N/A | N/A |
Dr. Mark Luscher Ph.D. | Senior Vice President of Scientific Affairs | 249,29k | N/A | N/A |
Mr. Philip Casselli | Senior Vice President of Sales, Business Development & Marketing | 265,1k | N/A | N/A |
Mr. Christopher B. Lobb | Compliance Officer, General Counsel & Secretary | N/A | N/A | N/A |
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
Microbix Biosystems Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.